Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Receivables (2017 - 2023)

VYNE Therapeutics' Change in Receivables history spans 5 years, with the latest figure at $16000.0 for Q3 2023.

  • For Q3 2023, Change in Receivables fell 90.42% year-over-year to $16000.0; the TTM value through Sep 2023 reached $244000.0, up 102.7%, while the annual FY2018 figure was -$786000.0, 200.0% down from the prior year.
  • Change in Receivables reached $16000.0 in Q3 2023 per VYNE's latest filing, down from $129000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $798000.0 in Q2 2021 to a low of -$8.0 million in Q1 2022.
  • Average Change in Receivables over 3 years is -$1.5 million, with a median of -$68000.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: crashed 128.95% in 2022, then skyrocketed 155.84% in 2023.
  • A 3-year view of Change in Receivables shows it stood at -$996000.0 in 2021, then soared by 116.77% to $167000.0 in 2022, then tumbled by 90.42% to $16000.0 in 2023.
  • Per Business Quant, the three most recent readings for VYNE's Change in Receivables are $16000.0 (Q3 2023), $129000.0 (Q2 2023), and -$68000.0 (Q1 2023).